Citations

Clear

479 citation(s) found for "Tobias, JS".

A review of mitotane in the management of adrenocortical cancer
Rivero, Jaydira Del , Else, Tobias , Hallanger‐Johnson, Julie , Kiseljak‐Vassiliades, Katja , Raj, Nitya , Reidy‐Lagunes, Diane , Srinivas, Sandy, Gilbert, Jill, Vaidya, Anand , Aboujaoude, Emily , Fojo, Tito , Del Rivero, Jaydira , Bancos, Irina , Tito Fojo, Antonio , Bancos, Irina

Mayo Clinic

The Oncologist | May 9, 2024 | Volume: 29 | Issue: 9 | Pages: 747-760

10.1093/oncolo/oyae084 | PMID 39037424 Get It

Abstract Importance Mitotane (Lysodren, o,p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane)] is currently the only United States Food and Drug Administration and European Medicines Agency-approved product for the treatment of adrenocortical carcinoma. Observations Mitotane is challenging to administer; however, its toxicities (specifically adrenal insufficiency) are well known, and the management of adverse consequences has established approaches. While often viewed through the prism of a cytotoxic agent, it can also interfere with hormone production making it a valuable asset in managing functional ACC. A recently completed prospective trial has shed some light on its use in the adjuvant setting, but further clarity is needed. Many think mitotane has a role in the advanced or metastatic setting, although prospective data are lacking and retrospective analyses are often difficult to interpret. Conclusions and relevance When used carefully and thoughtfully, especially in patients with hormonal excess, mitotane is an important component of the treatment armamentarium for ACC.
Predicting Disease Relapse in ANCA Associated Vasculitis With Radiomics
Falde, S., Rajagopalan, S., Cartin‐Ceba, Rodrigo , Peikert, Tobias, Specks, Ulrich , Bartholmai, Brian J. , Rajagopalan, S.

Mayo Clinic

B80-1. METHODOLOGICAL ADVANCEMENTS IN PULMONARY IMAGING | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A4502-A4502

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4502 Get It

Bronchoscopic Lung Volume Reduction: Machine Learning Mathematical Model for Target Lobe Selection
Hostetter, Logan , Brown, L. E. , Rajagopalan, S., Scrodin, M. Dulohery, Edell, E.S., Lester, Michael , Maldonado, Fabien , Lentz, Robert J. , Peikert, T., Brown, L., Rajagopalan, S., Edell, Eric S. , Bartholmai, Brian J. , Peikert, Tobias

Mayo Clinic

B21. RESEARCH STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A3065-A3065

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3065 Get It

A Novel Radiomics Tool for Early Detection of Idiopathic Pulmonary Fibrosis
Rajagopalan, S., Do, Quan , Nwakama, Chibuzo, Herberts, Michelle , McCoy, John J., Holmes, David R. , Peikert, Tobias, Limper, Andrew H. , Rajagopalan, S., Bartholmai, Brian J. , McCoy, J.J., III, D.R. Holmes,

Mayo Clinic

C23. MACHINE LEARNED: AI-DRIVEN SOLUTIONS IN ILD AND LUNG TRANSPLANT | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5103-A5103

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5103 Get It

Higher Asthma Prevalence Among Bronchiectasis Patients With Allergenic Molds in Respiratory Cultures
Chalmers, Sarah , Escalante, Patricio , Peikert, Tobias, Skalski, J., LIMPER, ANDREW H, Aksamit, Timothy R. , Kanj, Amjad , Limper, Andrew H.

Mayo Clinic

C68. NTM: CHALLENGING SCIENCE AND CASES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6304-A6304

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6304 Get It

A Case of Drug-Induced Pneumonitis From Trastuzumab-Deruxtecan for Metastatic Breast Cancer Refractory to High-Dose Steroids and Intravenous Immunoglobulin
Eggleston, R., Peikert, Tobias, Eggleston, R.H.

Mayo Clinic

B54. CASE REPORTS IN ONCOLOGIC TREATMENT-RELATED LUNG DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A3856-A3856

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3856 Get It

Characterization of Perioperative Serotonin in Patients Undergoing Orthotopic Liver Transplantation
Zott, Tobias , Kersten, Isabelle, Ortner, Max, Hüpper, Maria Noelle, Berlakovich, Gabriela , Silberhumer, Gerd R. , Berlakovich, Gabriela A , Silberhumer, Gerd R , Pereyra, David , Starlinger, Patrick

Mayo Clinic

Journal of Clinical Medicine | April 30, 2024 | Volume: 13 | Issue: 9 | Pages: 2640

10.3390/jcm13092640 | PMID 38731169 Get It

Background: Platelets were shown to be relevant for liver regeneration. In particular, platelet-stored serotonin (5-HT) proved to be a pro-regenerative factor in this process. The present study aimed to investigate the perioperative course of 5-HT and evaluate associations with patient and graft outcomes after othotopic liver transplantation (OLT). Methods: 5-HT was quantified in plasma and serum of 44 OLT recipients perioperatively, and in their respective donors. Olthoff’s criteria for early allograft dysfunction (EAD) were used to evaluate postoperative outcomes. Results: Patients with higher donor intra-platelet 5-HT per platelet (IP 5-HT PP) values had significantly lower postoperative transaminases (ASAT POD1: p = 0.006, ASAT POD5: p = 0.006, ASAT POD10: p = 0.02, ALAT POD1: p = 0.034, ALAT POD5: p = 0.017, ALAT POD10: p = 0.04). No significant differences were seen between postoperative 5-HT values and the occurrence of EAD. A tendency was measured that donor IP 5-HT PP is lower in donor-recipient pairs that developed EAD (p = 0.07). Conclusions: Donor IP 5-HT PP might be linked to the postoperative development of EAD after OLT, as higher donor levels are correlated with a more favorable postoperative course of transaminases. Further studies with larger cohorts are needed to validate these findings.
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Wagemann, Olivia , Shi, Xinyu , Bittner, Tobias , Scelsi, Marzia A. , Farlow, Martin R. , Clifford, David B. , Santacruz, Anna , Aschenbrenner, Andrew J. , Hassenstab, Jason , Gordon, Brian A. , Coalier, Kelley A., Perrin, Richard J., Xiong, Chengjie , Li, Yan , Morris, John C. , Lah, James J., Berman, Sarah , Roberson, Erik D. , Dyck, Christopher H. van, Gauthier, Serge , Pariente, Jérémie , Mummery, Catherine J. , Day, Gregory S. , Ringman, John M. , Méndez, Patricio Chrem, Fox, Nick C. , Okhravi, Hamid , Chhatwal, Jasmeer P. , Xiong, Chengjie , Sims, John R. , Holdridge, Karen C. , Proctor, Nicholas K. , Yaari, R. , Andersen, Scott W. , Mancini, Michele , Unit, Dominantly Inherited Alzheimer Network–Trials, Daniels, Alisha , Courtney, Laura, Lu, Ruijin , Gremminger, Emily, Franklin, Erin , Jerome, Gina, Herries, Elizabeth, Baker, Bryce, Minton, Matthew, Goate, Alison , Picarello, Danielle M. , Hornbeck, Russ C. , Chen, Allison , Chen, Charles D., Jarman, Steve, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Sabaredzovic, Edita, Smith, Hunter , Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Nadkarni, Neelesh K. , Graff‐Radford, Neill R. , Huey, Edward D. , Salloway, Stephen , Bechara, Jacob , Ryan, Natalie S. , Laske, Christoph , Hofmann, Anna, Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Obermueller, Ulrike, Roedenbeck, Yvonne, Sánchez‐Valle, Raquel , Vázquez, Silvia , Leon, Yudy Milena, Ramírez, Laura, Seyfried, Nicholas T. , Fagan, Anne M. , Mori, Hiroshi , Gordon, Brian A , Roberson, Erik , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , Liu, Haiyan , Wang, Guoqiao , Supnet, Charlene , Benzinger, Tammie L.S. , Cruchaga, Carlos , Ibanez, Laura , Li, Yan, Dyck, Christopher H. van , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Brooks, William S. , George‐Hyslop, Peter St , Suzuki, Kazushi , Jucker, Mathias , Mancini, Michele, Llibre‐Guerra, Jorge J. , Bateman, Randall J. , McDade, Eric , Unit, Dominantly Inherited Alzheimer Network–Trials, Xu, Xiong, Stauber, Jennifer, Renton, Alan , Flores, Shaney , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Smith, Jennifer A. , Stout, Sarah Holtz , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Noble, James M. , Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Martins, Ralph N. , Cash, David M. , Vöglein, Jonathan , Lee, Jae‐Hong , Roh, Jee Hoon , Rosa-Neto, Pedro , Allegri, Ricardo , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Levey, Allan I. , Johnson, Erik C. B. , Masters, Colin L.

Mayo Clinic

JAMA Neurology | April 29, 2024 | Volume: 81 | Issue: 6 | Pages: 582

10.1001/jamaneurol.2024.0991 | PMID 38683602 Get It

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P < .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P < .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242
Human-Computer Interaction: Impact of Artificial Intelligence on the diagnostic confidence of endoscopists assessing videos of Barrett’s esophagus
Röser, D, Meinikheim, M. , Mendel, Robert , Scheppach, Markus W. , Nagl, Sandra , Schnoy, Elisabeth , Schulz, Dominik , Schlottmann, J., Prinz, F., Rauber, David , Rückert, Tobias, Parsa, Nour, Messmann, H, Ebigbo, Alanna , Roser, David , Palm, Christoph , Probst, Andreas , Muzalyova, Anna , Römmele, Christoph , Matsumura, Tomoaki , Fernández‐Esparrach, Glòria , Byrne, Michael F.

Mayo Clinic

Endoscopy | April 23, 2024 | Volume: 56 | Issue: S 02 | Pages: S79-S79

10.1055/s-0044-1782859 Get It

Abstract 9600: Coronary Artery Disease Patients with Normal Body Mass Index but Central Obesity Have the Worst Long-Term Survival When Compared to Other Patterns of Adiposity
Coutinho, Thais , Sa, Daniel Correa de, Kragelund, Charlotte, Park, Jong‐Seon , Lorgis, Luc , Lee, Sang-Hee, Roger, Véronique L. , Goel, Kashish , Sa, Daniel Correa de, Kanaya, Alka M , Zeller, Marianne , Køber, Lars , Torp-Pedersen, Christian Tobias , Cottin, Yves , Lee, Sang-Hee, Kim, Young-Jo, Thomas, Randal J. , Somers, Virend K. , López-Jiménez, Francisco

Mayo Clinic

Circulation | April 23, 2024 | Volume: 124 | Issue: suppl_21 | Pages: No page available

10.1161/circ.124.suppl_21.a548 Get It

Thais Coutinho, 2011 Finalist and Presenting Author